Evidence map›Paper›PMID 29718892›Full record

Trial reportMedicine2018

Clinical application of oral meglumine diatrizoate esophagogram in screening esophageal fistula during radiotherapy for esophageal cancer.

Lidan Geng, Rong Wu, He Hu, Yu Zhao, Lingli Fan, Zhenhua Zhao, Dongbiao Liao, Musheng Li, Miao Xiang, Ying Ma and 1 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Lidan GengDepartment of Oncology, Mianyang Central Hospital, Mianyang Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nan Chong Department of Oncology, Yan Ting County Cancer Hospital, Yan Ting Department of Oncology Department of Radiology Department of Scientific Research and Education, Mianyang Central Hospital, Mianyang, People's Republic of China.
Rong Wu
He Hu
Yu Zhao
Lingli Fan
Zhenhua Zhao
Dongbiao Liao
Musheng Li
Miao Xiang
Ying Ma
Xiaobo Du
Mianyang Central Hospital · CNCM Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEsophageal fistula is a serious and common complication of radiotherapy for esophageal cancer. Therefore, early diagnosis and treatment is necessary. Because of side effect of barium esophagography, it cannot be used to screening esophageal fistula during radiotherapy. Meglumine diatrizoate is an ionic contrast agent, its adverse reactions were rarely seen when it was used in the body cavity. The purpose of this trial is identified the sensitivity and specificity of oral meglumine diatrizoate in an esophagogram for screening esophageal fistula during radiotherapy. METHODS/

designThis trial was a prospective, multicenter, diagnostic clinical trial. A total of 105 patients with esophageal cancer will swallowed meglumine diatrizoate and underwent a radiographic examination weekly during radiotherapy, medical personnel observed the esophageal lesions to determine whether an esophageal fistula formed. If an esophageal fistula was observed, esophagofiberoscopy and/or computer tomography was used to further confirm the diagnosis. And the sensitivity and specificity of meglumine diatrizoate should be calculated for screening esophageal fistula during radiotherapy. DISCUSSION: To our knowledge, this study protocol is the first to identify the sensitivity and specificity of oral meglumine diatrizoate in an esophagogram for screening esophageal fistula during radiotherapy. If oral meglumine diatrizoate can be used to screening esophageal fistula, more patients will benefit from early detection and treatment.

Indexed as

Esophageal NeoplasmsAdultChinaContrast MediaDiatrizoate MeglumineEarly DiagnosisEsophageal FistulaFemaleHumansMaleMass ScreeningRadiographyRadiotherapySensitivity and SpecificityContrast MediaDiatrizoate Meglumine

Identifiers

PMID29718892
PMCPMC6393137
OpenAlexW2799271316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.